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ABSTRACT
Objective
To evaluate the association between migraine and
incident cardiovascular disease and cardiovascular
mortality in women.
Design
Prospective cohort study among Nurses’ Health Study
II participants, with follow-up from 1989 and through
June 2011.
Setting
Cohort of female nurses in United States.
Participants
115 541 women aged 25-42 years at baseline and free of
angina and cardiovascular disease. Cumulative
follow-up rates were more than 90%.
Main outcome measures
The primary outcome of the study was major
cardiovascular disease, a combined endpoint of
myocardial infarction, stroke, or fatal cardiovascular
disease. Secondary outcome measures included
individual endpoints of myocardial infarction, stroke,
angina/coronary revascularization procedures, and
cardiovascular mortality.
Results
17 531 (15.2%) women reported a physician’s diagnosis
of migraine. Over 20 years of follow-up, 1329 major
cardiovascular disease events occurred and 223
women died from cardiovascular disease. After
adjustment for potential confounding factors, migraine
was associated with an increased risk for major
cardiovascular disease (hazard ratio 1.50, 95%
confidence interval 1.33 to 1.69), myocardial infarction
(1.39, 1.18 to 1.64), stroke (1.62, 1.37 to 1.92), and
angina/coronary revascularization procedures (1.73,
1.29 to 2.32), compared with women without migraine.
Furthermore, migraine was associated with a
significantly increased risk for cardiovascular disease
mortality (hazard ratio 1.37, 1.02 to 1.83). Associations
were similar across subgroups of women, including by

What is already known on this topic
Migraine has been consistently linked with increased risk of ischemic stroke
Few studies have shown an association of migraine with coronary events and
cardiovascular mortality

What this study adds
Analysis of data from a large prospective cohort study in women show that migraine
is associated with any cardiovascular disease, including coronary events and
cardiovascular mortality
These results further add to the evidence that migraine should be considered an
important risk marker for cardiovascular disease, at least in women
the bmj | BMJ 2016;353:i2610 | doi: 10.1136/bmj.i2610

age (<50/≥50), smoking status (current/past/never),
hypertension (yes/no), postmenopausal hormone
therapy (current/not current), and oral contraceptive
use (current/not current).
Conclusions
Results of this large, prospective cohort study in
women with more than 20 years of follow-up indicate a
consistent link between migraine and cardiovascular
disease events, including cardiovascular mortality.
Women with migraine should be evaluated for their
vascular risk. Future targeted research is warranted to
identify preventive strategies to reduce the risk of
future cardiovascular disease among patients with
migraine.

Introduction
Migraine is a primary headache disorder that affects
approximately one fifth of the general US population for
at least part of their lives, and women are affected three
to four times more often than men.1-3 Migraine, specifically migraine with aura, has been consistently associated with increased risk of stroke, including both
ischemic and hemorrhagic subtypes.4 5 Although the
pathophysiology of migraine has close links to the vascular system, the mechanisms by which migraine
increases risk of stroke remain unclear.6 7 Potential
mechanisms for an association between migraine and
stroke include endovascular dysfunction,8 9 increased
thrombogenic susceptibility,10 increased prevalence of
vascular risk factors,11 shared genetic markers,12 13 cortical spreading depolarization,14 15 and inflammation.16 17
As most of these mechanisms also increase the risk of
other cardiovascular disease events, migraine may be
viewed as a marker of increased risk for any vascular
disease event. However, as the one year prevalence of
migraine peaks in midlife whereas the incidence of cardiovascular events increases exponentially with age,
links between migraine and any cardiovascular disease
are not easily identifiable. Long follow-up, particularly
of younger populations, is needed to study this association. Few prospective studies have reported an association between migraine and any cardiovascular disease
events,18-21 including ischemic heart disease and cardiovascular death.18 20 21
Because of the high prevalence of migraine, any
association between migraine and cardiovascular disease would have a substantial effect on public health.
We thus aimed to evaluate the association of migraine
with total and specific cardiovascular disease events as
well as cardiovascular disease specific mortality in the
Nurses’ Health Study II, one of the largest prospective
cohort studies on health in younger women, aged 25 to
42 at baseline.
1
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Methods
Study population
Established in 1989, the Nurses’ Health Study II is an
ongoing prospective cohort study of 116 430 female registered nurses in the United States who were 25-42 years
old at baseline. Information on reproductive factors,
lifestyle factors, and medical history was collected
through a self administered questionnaire at baseline
and has been updated every two years through
follow-up questionnaires. The cumulative response rate
based on person time is more than 90%. For the purpose of this analysis, we included follow-up from baseline through June 2011. We excluded 889 women who
reported cardiovascular disease at baseline (angina, a
coronary revascularization procedure, myocardial
infarction, or stroke) from our analyses, leaving 115 541
women free of angina or any symptomatic cardiovascular disease for our analyses.
Patient involvement
No patients were involved in setting the research question or the outcome measures, nor were they involved in
developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on
interpretation or writing up of results. Results of the
study will be disseminated to patients’ organizations
and via the webpage of the Nurses’ Health Study
(http://www.nurseshealthstudy.org).
Assessment of migraine
On the baseline (1989) and two follow-up questionnaires (1993 and 1995), women were asked to indicate
whether a physician had diagnosed them as having
migraine. Person time status for having a migraine
started whenever migraine was first reported. Agreement between self reported migraine and 2004 International Headache Society criteria was high in another
comparable cohort of female health professionals.22
Information on migraine aura, migraine frequency, or
migraine specific drugs was not available.
Ascertainment of cardiovascular disease events
Every two years, women reported any incident cardiovascular disease event on the follow-up questionnaires
and then completed a supplemental questionnaire confirming the event. Self reported information on cardiovascular disease was confirmed through review of
medical record or supporting information by a physician who was blinded to the exposure status and the
specific research question under study. Deaths were
identified by reports from next of kin, from postal
authorities, or by searching the National Death Index.
At least 98% of deaths among the Nurses’ Health Study
II participants were identified using these approaches.23
Causes of death were confirmed by review of autopsy
reports, medical records, and death certificates.
The occurrence of non-fatal myocardial infarction
was confirmed if symptoms met World Health Organization criteria, which require typical symptoms plus
either diagnostic electrocardiographic findings or elevated cardiac enzyme concentrations.24 If medical
2

records were unavailable, we considered myocardial
infarctions probable when additional confirmatory
information was provided by the participant. Information on angina and coronary revascularization procedures (percutaneous transluminal coronary angioplasty
or coronary artery bypass grafting surgery) was self
reported, and we included only events that occurred
before a manifest cardiovascular disease event.
A non-fatal stroke diagnosis was confirmed, according to National Survey of Stroke criteria, if the participant had a new focal neurologic deficit with sudden or
rapid onset that persisted for more than 24 hours.25 We
excluded cerebrovascular pathology due to infection,
trauma, or malignancy, as well as “silent” strokes discovered only by radiologic imaging. Radiology reports
of brain imaging (computed tomography or magnetic
resonance imaging) were available in 89% of those with
medical records. We classified strokes as ischemic
stroke (thrombotic or embolic occlusion of a cerebral
artery), hemorrhagic stroke (subarachnoid and intraparenchymal hemorrhage), or stroke of probable/
unknown subtype (a stroke was documented but the
subtype could not be ascertained owing to medical
records being unobtainable).
Fatal cardiovascular disease was defined as fatal coronary heart disease, fatal stroke, or fatal cardiovascular
disease. Fatal coronary heart disease was defined as
ICD-9 (international classification of diseases, ninth revision) codes 410-412 and was considered confirmed if fatal
coronary heart disease was confirmed via medical records
or autopsy reports or if coronary heart disease was listed
as the cause of death on the death certificate and there
was prior evidence of coronary heart disease in the medical records. We designated as probable those cases in
which coronary heart disease was the underlying cause
on the death certificates but no prior knowledge of coronary heart disease was indicated and medical records
concerning the death were unavailable. Similarly, we
used ICD-9 codes 430-434 to define fatal stroke and followed the same procedures to classify cases of confirmed
or probable fatal stroke. Lastly, fatal cardiovascular disease was defined by ICD-9 codes 390-458.
Our primary outcome measure was major cardiovascular disease, a combined endpoint of myocardial
infarction, stroke, or fatal cardiovascular disease (fatal
stroke, fatal myocardial infarction, and fatal coronary
heart disease). We chose this composite outcome as it
has been used as outcome in previous studies,18 26 and it
follows guidelines on prevention of all cardiovascular
disease to capture the full impact of risk factors and cardiovascular health.27 We further assessed the following
secondary outcome measures: total myocardial infarction, which was defined as fatal or non-fatal myocardial
infarction; total stroke, which included all fatal and
non-fatal stroke cases (ischemic, hemorrhagic, and
undetermined subtypes); angina/coronary revascularization procedure; and cardiovascular disease mortality.

Statistical analyses
We calculated person time from the return date of the
1989 questionnaire until the date of diagnosis of
doi: 10.1136/bmj.i2610 | BMJ 2016;353:i2610 | the bmj
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c ardiovascular disease, date of death, or end of follow-up (June 2011), whichever occurred first. We used
Cox proportional hazards models with age and two year
follow-up cycle as timescale to evaluate the association
between migraine and the various outcomes. We calculated age adjusted and multivariable adjusted hazard
ratios and corresponding 95% confidence intervals. The
multivariable adjusted models controlled for age (continuous), elevated cholesterol (yes/no), diabetes (yes/
no), hypertension (yes/no), body mass index (<25,
25-<30, ≥30), smoking status (never, past, current),
alcohol consumption (0, 0-14.9, ≥15 g/day), physical
activity (metabolic equivalent of tasks (METs) in fifths)
(continuous), postmenopausal hormone use (never,
past, current), menopausal status (premenopausal,
postmenopausal, dubious), ever used oral contraceptive
Table 1 | Age standardized baseline characteristics (1989) according to migraine status in
Nurses’ Health Study II (n=115 541). Values are percentages unless stated otherwise
Characteristics

Mean (SD) age*, years
Body mass index†:
<25
25 to <30
≥30
History of hypertension
History of hypercholesterolemia
History of diabetes
Smoking status:
Never
Past
Current
Alcohol consumption, g/day:
0
>0 to 14.9
≥15
Mean (SD) physical activity, METs/week
Menopausal status:
Premenopausal
Postmenopausal
Dubious/unknown
Postmenopausal hormone use:
Never
Past
Current
Oral contraceptive use:
Never
Past
Current
Family history of myocardial infarction
Aspirin use:
<2 days/week
≥2 days/week
Acetaminophen (paracetamol) use:
<2 days/week
≥2 days/week
Non-steroidal anti-inflammatory drug use:
<2 days/week
≥2days/week

No migraine
(n=98 010)

Migraine
(n=17 531)

34.2 (4.7)

35.1 (4.5)

70.1
18.3
10.9
4.9
9.7
0.8

65.5
19.9
13.9
8.6
14.7
1.00

65.5
21.2
13.2

62.6
22.3
15.0

37.1
58.8
3.1
24.9 (36.8)

39.4
57.6
2.3
24.9 (36.7)

97.4
2.0
0.4

95.3
4.00
0.5

89.2
6.9
3.3

83.3
9.9
6.1

17.1
69.6
13.2
14.3

13.4
74.8
11.7
17.5

89.9
10.1

83.2
16.8

80.0
20.0

66.9
33.1

82.6
17.4

69.7
30.3

Percentages may not add to a 100% because of rounding or missing values.
MET=metabolic equivalent.
*Value is not age adjusted.
†Calculated as weight in kilograms divided by height in meters squared.

the bmj | BMJ 2016;353:i2610 | doi: 10.1136/bmj.i2610

(never, past, current), aspirin use (<2 days/week,
≥2 days/week), acetaminophen (paracetamol) use
(<2 days/week, ≥2 days/week), non-steroidal anti-
inflammatory drug use (<2 days/week, ≥2 days/week),
and family history of myocardial infarction before the
age of 60 (yes/no). We adjusted for all the covariates in
the models in a time varying fashion on the basis of
information available on each of the biennial questionnaires (1991 to 2009).
We evaluated effect modification by age (<50/≥50),
smoking status (current/past/never), hypertension
(yes/no), postmenopausal hormone therapy (current/
not current), and oral contraceptive use (current/not
current). We tested effect modification by including an
interaction term for migraine and the potential effect
modifier in the outcome models.
We tested the proportional hazards assumption by
including an interaction term for migraine status and
the logarithm of follow-up time for the primary outcomes in age adjusted models. We found no statistically
significant violation. In sensitivity analyses, we
repeated the analyses on the basis of migraine information provided at baseline only.
We had 3.1% missing information on all covariates
and used a missing variable indicator to account for this
lack of information in our multivariable models. In sensitivity analyses, we used multiple imputation (proc mi)
to account for missing information and also ran a model
excluding all missing information.
We used SAS 9.3 for all analyses. All P values were
two sided, and we considered a P value of less than 0.05
to be statistically significant.

Results
Of the 115 541 women in this study, 17 531 (15.2%)
reported a physician’s diagnosis of migraine at baseline
in 1989. An additional 6389 women newly reported a
physician’s diagnosis on subsequent questionnaires
and were classified having migraine during follow-up.
Women with migraine were more likely to have an unfavorable cardiovascular risk factor profile, including
hypertension, hypercholesterolemia, family history of
myocardial infarction, body mass index of 30 or above,
and current smoking status. They were also more likely
to use aspirin, acetaminophen, and non-steroidal
anti-inflammatory drugs (table 1).
Table 2 summarizes the associations between
migraine and various cardiovascular outcomes. During
follow-up, 1329 major cardiovascular disease events
(678 total myocardial infarctions, 651 total strokes, and
203 angina/coronary revascularization procedures)
occurred. A total of 223 deaths due to cardiovascular
disease occurred. Compared with women without
migraine, those with a self reported physician’s diagnosis of migraine had a multivariable adjusted hazard
ratio of 1.50 (95% confidence interval 1.33 to 1.69) for
developing major cardiovascular disease. Findings
were significant for all evaluated individual outcomes,
and the highest estimates were seen for stroke (hazard
ratio 1.62, 1.37 to 1.92) and angina/coronary revasculari
zations (1.73, 1.29 to 2.32).
3
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Table 2 | Age adjusted and multivariable adjusted hazard ratios for cardiovascular
disease outcomes according to migraine status in Nurses’ Health Study II (n=115 541)
Hazard ratio (95% CI)
Outcome

Major cardiovascular disease event (n=1329):
Age adjusted
Multivariable adjusted
Myocardial infarction (n=678):
Age adjusted
Multivariable adjusted
Stroke (n=651):
Age adjusted
Multivariable adjusted
Angina/coronary revascularization (n=203):
Age adjusted
Multivariable adjusted
Cardiovascular mortality (n=223):
Age adjusted
Multivariable adjusted

No migraine
(n=98 010)

Any migraine
(n=17 531)

P value

1.00
1.00

1.84 (1.64 to 2.06)
1.50 (1.33 to 1.69)

<0.01
<0.01

1.00
1.00

1.79 (1.52 to 2.10)
1.39 (1.18 to 1.64)

<0.01
<0.01

1.00
1.00

1.89 (1.60 to 2.22)
1.62 (1.37 to 1.92)

<0.01
<0.01

1.00
1.00

2.35 (1.77 to 3.12)
1.73 (1.29 to 2.32)

<0.01
<0.01

1.00
1.00

1.66 (1.25 to 2.21)
1.37 (1.02 to 1.83)

<0.01
0.04

Multivariable models were adjusted for age (continuous), elevated cholesterol (yes/no), diabetes (yes/no),
hypertension (yes/no), body mass index (<25, 25-29.9, ≥30), smoking status (never, past, current), alcohol
consumption (0, >0-14.9, ≥15g/day), physical activity (METs in fifths), postmenopausal hormone use (never, past,
current), menopausal status (premenopausal, postmenopausal, dubious), ever used oral contraceptive (never,
past, current), aspirin use (<2, ≥2 days/week), acetaminophen (paracetamol) use (<2, ≥2 days/week),
non-steroidal anti-inflammatory drug use (<2, ≥2 days/week), and family history of myocardial infarction before
age of 60 (yes/no).

The associations between migraine and cardiovascular disease outcomes (major cardiovascular disease, total
myocardial infarction, and total stroke) were not modified by age (<50/≥50) (P for interaction all ≥0.34), current
postmenopausal hormone use (P for interaction all
≥0.57), current oral contraceptive use (P for interaction
all ≥0.84), current smoking status (P for interaction all
≥0.26), or hypertension (P for interaction all ≥0.37). In
sensitivity analyses, we restricted analysis to women
with a report of migraine at baseline. The multivariable
adjusted hazard ratios were 1.57 (1.38 to 1.77) for major
cardiovascular disease, 1.77 (1.49 to 2.11) for total stroke,
and 1.39 (1.17 to 1.66) for total myocardial infarction. The
results of the association between migraine and major
cardiovascular disease were very similar when we used
multiple imputation (hazard ratio 1.50, 1.33 to 1.71) or
when we excluded missing information (1.53, 1.35 to 1.74).

Discussion
In this large, prospective cohort study of female nurses
aged 25 to 42 at inclusion who were free of cardiovascular disease at the start of follow-up and with more than
20 years of follow-up, we found consistent associations
between migraine and cardiovascular disease events.
We found an approximately 50% increased risk for
major cardiovascular disease. This association persisted after adjustment for traditional vascular risk factor and was apparent for myocardial infarction, stroke,
and coronary artery procedures as well as for angina.
We also found an increased risk of cardiovascular disease mortality.
Comparison with other studies
Most studies evaluating the association between
migraine and vascular events have been limited to
4

ischemic stroke.4 28 Some studies have reported an
association between migraine and cardiovascular disease.18-21 Results of our study are in line with findings
from the Women’s Health Study,18 another large prospective cohort study among female health professionals aged 45 or older at inclusion. In the Women’s Health
Study, migraine was associated with an increased risk of
major cardiovascular disease events (hazard ratio 1.42,
95% confidence interval 1.16 to 1.074), including cardiovascular disease mortality (1.63, 1.07 to 2.50). In the
Women’s Health Study, the increased risk was apparent
only for women who reported migraine with aura. In our
study, information on aura was not available.
In a matched cohort study of 11 541 patients with
migraine who were aged 18 to 45 years and an equal
number of controls from the Taiwan National Health
Insurance database, Wang and colleagues reported an
increased risk of ischemic heart disease for people with
migraine (hazard ratio 2.50, 1.78 to 3.52).20 The Reykjavik Study, which included 18 725 men and women,
showed very similar results for the association between
overall migraine and cardiovascular disease mortality.21
After adjustment for potential confounders, participants with any indication of migraine had a 16%
increased risk of dying from any cause (hazard ratio
1.16, 1.04 to 1.29). This risk was stronger for people with
migraine with aura (hazard ratio 1.21, 1.12 to 1.30) and
was higher for mortality from cardiovascular disease
(1.27, 1.13 to 1.43) compared with people without headache. Results from the American Migraine Prevalence
and Prevention study also indicate an increased risk of
cardiovascular disease events. In this population based
case-control study of 6102 patients with migraine and
5243 controls, migraine overall was associated with a
relative risk for myocardial infarction of 2.16 (1.70 to
2.76) and for total stroke of 1.54 (1.16 to 2.05).19
Two studies have found an association between
migraine with aura and angina but not myocardial
infarction.29 30 The lack of association with myocardial
infarction may be related to shorter follow-up time. In
our data, women with migraine had an increased risk
for myocardial infarction, as well as for angina and coronary revascularization procedures.
Many studies have focused on the evaluation of
potential modifying factors and on the identification of
a subgroup of patients with migraine who are at high
risk for developing a subsequent stroke. Studies have
consistently found that the association between
migraine and stroke was observable only among
younger people and was stronger among women.28
Among women, several studies have focused on the role
of smoking and oral contraceptive use.28 31 32 In particular, the combination of smoking and oral contraceptive
use among young women with migraine with aura
markedly increased the risk of ischemic stroke, reaching a 10-fold increase for current cigarette smokers and
oral contraceptives users.33 However, for overall
vascular risk status, several studies indicate that the
association between migraine and ischemic stroke is
apparent only among those with a low cardiovascular
risk profile.33 34
doi: 10.1136/bmj.i2610 | BMJ 2016;353:i2610 | the bmj
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Studies on modifying effects of other cardiovascular
disease events are sparse. Findings of the Women’s
Health Study indicate that migraine with aura and an
increased vascular risk profile resulted in a higher risk
of incident myocardial infarction.34 However, the event
rate among women with migraine with aura was still
too small to robustly evaluate the role of individual vascular risk factors, including postmenopausal hormone
use.

Potential biological mechanisms
Several mechanisms that have been implied for
migraine have also been linked with increased risk of
cardiovascular disease, such as increased thrombogenic susceptibility,10 shared genetic markers,12 13 and
inflammation processes.16 17 Our findings confirm
results of other studies that women with migraine have
a higher prevalence of vascular risk factors, such as
hypertension, higher body mass index, and hypercholesterolemia.11 19 However, as all studies evaluating the
association between migraine and cardiovascular disease have controlled for these factors, the association
between migraine and cardiovascular disease is
unlikely to be explained by this. Evidence suggests that
the pathophysiology of migraine can also be viewed in
part as a systemic disorder affecting the endovascular
system.9 35-39
Strengths and limitations of study
Our study has several strengths, including the prospective design, large number of participants and outcome
events, long follow-up, high participation rate, standardized evaluation of migraine and cardiovascular
disease risk factors, confirmation of outcomes by physician’s review, and the homogeneous nature of the
cohort (all were nurses), which may reduce confounding by factors such as access to medical care.
Several limitations should be considered when interpreting our results. Firstly, physician diagnosed
migraine status was self reported, leading to potential
misclassification. In addition, people with mild
migraines may not have reported symptoms to a clinician and thus not received a diagnosis. Because of the
prospective design, however, such misclassification
would probably result in underestimation of relative
risks and would be unlikely to explain the observed
association pattern. Furthermore, a previous report in a
comparable study of female health professionals
showed that self reported migraine had good agreement
with the second edition of the International Classification of Headache Disorders,22 and our prevalence of
migraine is close to that reported in other population
based studies.18 40 41 Secondly, we had no information
on the presence or absence of migraine aura, and
migraine with aura has been suggested to be the subgroup carrying most of the risk of cardiovascular disease.4 18 Furthermore, no information on frequency of
migraine or migraine specific information was available. Thirdly, residual confounding—for example, by
markers of inflammation or genetic factors10 12 13—
remains a potential alternative explanation, as our data
the bmj | BMJ 2016;353:i2610 | doi: 10.1136/bmj.i2610

are observational. Finally, participants in this study
were all nurses aged 25 to 42 at baseline and mostly
white, so generalizability to other populations might be
limited. However, we have no reason to believe that that
the biological mechanisms by which migraine might be
associated with vascular events and mortality would be
different in other populations of women.

Implications of findings
The results of our study support the findings of other
population based studies linking migraine with
increased risk of cardiovascular disease.18-20 Although
most studies link migraine with aura with increased
risk of ischemic stroke,4 28 emerging evidence indicates
that this risk extends to other cardiovascular disease as
well. Our data support consideration of a history of
migraine as a marker for increased risk of any cardiovascular disease event.
To date, no clear mechanisms have been identified
that could explain the increased risk of cardiovascular
disease and mortality among patients with migraine,
and no data exist on whether prevention of migraine
attacks reduces these risks. Data from the National
Health and Nutrition Examination Survey and results of
a randomized clinical trial provide initial evidence that
the combination of a statin and vitamin D may reduce
the burden of migraine,42 43 which may be explained by
the anti-inflammatory effects of these drugs. Future targeted research, such as on whether statins and vitamin
D reduce the burden of migraine and cardiovascular
disease, is urgently warranted to provide answers to
patients and their treating physicians.
Conclusions
Results of this large, prospective cohort study among
women support the hypothesis that migraine is a
marker for increased risk of any cardiovascular events.
Given the high prevalence of migraine in the general
population, an urgent need exists to understand the
biological processes involved and to provide preventive
solutions for patients.
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